Henny J M Beckers1, Carroll A B Webers, Michiel J W M Busch, Hendrik M A Brink, Thomas P Colen, Jan S A G Schouten. 1. University Eye Clinic, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Ophthalmology, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Ophthalmology, Jeroen Bosch Hospital, 's Hertogenbosch, The NetherlandsDepartment of Ophthalmology, Amphia Hospital Langendijk, Breda, The Netherlands.
Abstract
PURPOSE: To study the effect of patient education and the TravAlert(®) -Eyot(®) drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert(®) dosing aid. METHODS: Multicentre, randomized, controlled clinical trial among 18 Dutch hospitals. Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education. IOP was recorded at baseline and after 3 and 6 months. Data on adherence generated by the dosing aid were collected and studied at the end of the study. RESULTS:Mean IOP dropped from 20.3 ± 5.7 mmHg at baseline to 16.3 ± 4.0 mmHg (right eye) after 6 months and from 20.2 ± 5.9 mmHg to 16.4 ± 4.1 mmHg (left eye). The mean adherence rate was 0.91 ± 0.1. IOP and adherence rate were not statistically different between the study arms. Patients with 'drug holidays' had a significantly higher mean IOP after 6 months. Patients who used the drop guider were less adherent. A lower adherence level was also associated with new patients with glaucoma and patients with a lower level of knowledge on glaucoma. CONCLUSION: Patient education is especially useful for new patients with glaucoma. The use of a drop guider does not improve adherence. Especially patients with 'drug holidays' are at risk for developing uncontrolled IOP levels.
RCT Entities:
PURPOSE: To study the effect of patient education and the TravAlert(®) -Eyot(®) drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert(®) dosing aid. METHODS: Multicentre, randomized, controlled clinical trial among 18 Dutch hospitals. Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education. IOP was recorded at baseline and after 3 and 6 months. Data on adherence generated by the dosing aid were collected and studied at the end of the study. RESULTS: Mean IOP dropped from 20.3 ± 5.7 mmHg at baseline to 16.3 ± 4.0 mmHg (right eye) after 6 months and from 20.2 ± 5.9 mmHg to 16.4 ± 4.1 mmHg (left eye). The mean adherence rate was 0.91 ± 0.1. IOP and adherence rate were not statistically different between the study arms. Patients with 'drug holidays' had a significantly higher mean IOP after 6 months. Patients who used the drop guider were less adherent. A lower adherence level was also associated with new patients with glaucoma and patients with a lower level of knowledge on glaucoma. CONCLUSION:Patient education is especially useful for new patients with glaucoma. The use of a drop guider does not improve adherence. Especially patients with 'drug holidays' are at risk for developing uncontrolled IOP levels.
Authors: Cecilia N Hollenhorst; Vanessa Elliott; Michele Heisler; Kevin Schneider; Ken Resnicow; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2020-05-07
Authors: Dena Ballouz; Juno Cho; Maria A Woodward; Angela R Elam; David C Musch; Jason Zhang; Sayoko E Moroi; Leroy Johnson; Jean Cederna; Paula A Newman-Casey Journal: J Glaucoma Date: 2021-05-01 Impact factor: 2.290
Authors: Heidi Cate; Debi Bhattacharya; Allan Clark; Richard Fordham; Richard Holland; David C Broadway Journal: BMC Ophthalmol Date: 2014-03-24 Impact factor: 2.209